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ABSTRACT An Epstein-Barr virus-encoded protein,
ZEBRA, mediats the switch from latency to the viral lytic life
cycle. ZEBRA's domain structure and DNA binding specificity
resemble that of ceflular trnscriptional activators such as
c-Fos/c-Jun. We show that ZEBRA, like c-Jun, is phosphor-
ylated by casein kinase II (CKII). The principal site of phos-
phorylation is serine-173 (S173), five amino adds upstream of
the basic DNA recognition domain. CKII phosphorylation
abrogated ZEBRA's capacity to bind its targetDNA sequences.
S173 is a functional component of ZEBRA's DNA binding
domain, since mutation of S173 to alanine (S173A) reduced
DNA binding in vitro to 10% of wild-type levels. Transcrip-
tional activation of a native viral promoter in vivo by mutant
S173A was also reduced markedly. Reversible phosphorylation
of S173 is likely to be an important means of regulating
ZEBRA's activity in vivo.
Epstein-Barr virus (EBV) can be switched from latency into
the viral lytic cycle by expression of a virally encoded
protein, ZEBRA (1, 2). ZEBRA binds DNA and activates
transcription from promoters of early viral lytic cycle genes
(3, 4). Several other proteins that regulate EBV gene expres-
sion are encoded among these early lytic cycle genes (5, 6).
The C terminus of ZEBRA encodes a DNA binding domain
composed of basic amino acids (basic domain) followed by a
protein homodimerization domain. This organization is sim-
ilar to the basic zipper (bZIP) motiffound in many transcrip-
tional activators (7-9) (Fig. 1A). ZEBRA is homologous to
bZIP proteins of the c-Fos/c-Jun family in the basic DNA
recognition domain. Furthermore, ZEBRA and c-Fos/c-Jun
share the ability to bind a heptamer AP-1 consensus site (10).
ZEBRA also binds other heptamerDNA sequences (ZEBRA
response elements; ZREs) not bound by c-Fos/c-Jun (4,
15-17).
Cellular kinases such as casein kinase II (CKII) regulate
the activity of many nuclear DNA binding proteins (18-21).
CKII, a ubiquitous protein kinase present in both the cyto-
plasm and nucleus of eukaryotic cells, catalyzes the phos-
phorylation of serine or threonine residues N-terminal to
clusters of acidic amino acids (22, 23). Although CKII
activity can be detected in resting cells, it is elevated in cells
treated with mitogens (24-26). Thus, CKII may play a role in
signal transduction and regulation of cell division.
CKII can exert positive or negative effects on DNA
binding by cellular nuclear proteins that participate in the
transcriptional response to mitogens or DNA damage. For
example, CKII phosphorylation inhibits DNA binding by the
protooncoprotein c-Myb but enhances the DNA binding
activity of serum response factor (SRF) (27, 28). The pro-
tooncoprotein c-Myc and its in vivo heterodimer mate, Max,
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are both phosphorylated by CKII (12, 29) (Fig. 1B). Phos-
phorylated Max homodimers fail to bind DNA in vitro;
however, phosphorylated Myc/Max heterodimers do bind
DNA (13). c-Jun can be phosphorylated by CKII, although
the effect of this modification on DNA binding is not clear
(11, 30). In addition to DNA binding, other properties of
transcription factors such as nuclear localization, transacti-
vation, or transrepression are influenced by phosphorylation
by CKII (21).
We determined whether the activity of ZEBRA, a viral
immediate early transcriptional activator, is influenced by
phosphorylation. We found that phosphorylation ofZEBRA
by CKII inhibited DNA binding. ZEBRA contains two po-
tential CKII acceptor sites, serine-167 and -173 (S167 and
S173), in an acidic domain N-terminal to the basic DNA
recognition domain (10) (Fig. 1B). By examining proteins
mutated at these potential acceptor sites for their ability to be
phosphorylated by CKII in vitro, we mapped the principal
phosphorylation site to S173. We found that ZEBRA mutants
in which S173 was mutated to alanine (S173A) were markedly
inhibited in their ability to bind DNA and to activate tran-
scription of a ZEBRA-inducible viral early gene.
METHODS AND MATERIALS
Plasmids. Plasmid constructs expressing full-length or de-
leted ZEBRA as TrpE fusion proteins in Escherichia coli
have been described (17, 31). ZEBRA mutants S167A and
S173A were constructed by PCR-based mutagenesis (32). To
make S167A, the oligonucleotide 5'-GAATCGCATTCCTC-
CAGCG(CTTCTGG-3' (single point mutation underlined)
and an oligonucleotide in vector sequences were used to
prime the wild-type ZEBRA cDNA. The reaction product
was cut at both ends with Bsm I and ligated to a Bsm I cut
TrpE-ZEBRA expression construct. Similarly, the mutant
S173A was constructed by using 5'-TATTTCTAGTTCAG-
CATCGC-3', cutting the PCR product and the TrpE-ZEBRA
expression construct with Nhe I and Rma I and ligating.
ZEBRA S167A/S173A was constructed by swapping the
Bsm I fragment from ZEBRA S167A into ZEBRA S173A.
ZEBRA M187-189 has basic amino acids RKC in the DNA
recognition domain replaced with EES (17). ZEBRA coding
sequences were transferred by using convenient polylinker
restriction sites to the pSP64 or pSP65 expression vectors for
in vitro transcription and to the cytomegalovirus virus eu-
karyotic expression vector pHD1013 for use in B-cell trans-
fections (33).
Protein Expression. TrpE fusion proteins were expressed in
E. coli AG1 (31). ZEBRA protein was also expressed in E.
Abbreviations: EBV, Epstein-Barr virus; ZRE, ZEBRA response
element; CKII, casein kinase II; SRF, serum response factor;
EMSA, electrophoretic mobility-shift assay; PPMA, protein phos-
phatase 2A; CAT, chloramphenicol acetyltransferase.
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FIG. 1. Phosphorylation of ZEBRA. (A) Schematic representation of three related domains of ZEBRA and c-Jun: an acidic domain with
known or potential sites for phosphorylation by CKII; the basic domain; and the dimerization domains, coiled-coil and leucine zipper. (B) Amino
acid sequences N-terminal to the basic domains ofZEBRA and several human immediate early genes. Potential CKII acceptor sites are boxed
in ZEBRA (10). Known CKII phosphorylation sites are boxed in c-Jun (11), c-Myc (12), and Max (13). c-Fos may be phosphorylated by p34cdc2
kinase at S133 (14). (C) Phosphorylation ofZEBRA by casein kinase II as described in Results. Casein and TrpE proteins were used as controls.
Phosphorylated species are indicated by arrowheads. Autophosphorylation of the 8 subunit of CKII in each lane is indicated by Beta-CKII.
coli from the tac expression vector pRW76, purified, and
judged to be 90% pure by Coomassie blue staining of SDS/
polyacrylamide gel (34). In vitro transcribed/translated ZE-
BRA derivatives radiolabeled with [35S]cysteine and [35S]me-
thionine (Trans-35; ICN) were made in wheat germ extracts
(Promega). Protein/protein cross-links were performed with
3 Al of labeled translation product diluted in 0.004% glutar-
aldehyde for 30 min.
Protein Phosphorylations. Cell extracts containing 300 ng of
fusion protein or purified ZEBRA protein (100 ng) were
phosphorylated in CKII buffer (75 mM KCl/5 mM MgCl2/10
mM Hepes, pH 7.9/1 mM EGTA/0.5 mM dithiothreitol) in
the presence of 10 1.Ci of [y-32P]ATP (1 Ci = 37 GBq) and
CKII purified from bovine liver [88 pmol of casein phosphor-
ylated in 10 min in the presence of0.1mM ATP (24)]. Samples
were incubated at 37°C for 15 min.
Electrophoretic Mobility-Shift Assays (EMSAs). EMSAs
were performed in 30 A4 of CKII buffer using 100 ng of
purified ZEBRA protein or cell extract containing 300 ng of
ZEBRA fusion protein, with or without 0.33 ,uM ATP (Phar-
macia) and CKII. Some extracts were then exposed to 5-10
units of protein phosphatase 2A (PP2A; in 50 mM Tris HCl,
pH 7.5/0.1% bovine serum albumin) for an additional 15 min.
Samples were analyzed by EMSA with 0.4 pM double-
stranded AP-1, ZIIIB, or double oligonucleotides (17) that
had been radiolabeled by standard methods (32). Conversion
to bound oligonucleotide was quantitated by scintillation
counting.
B-Cell Gene Transfer and Chloramphenicol Acetyltrans-
ferase (CAT) Assays. Transcriptional activation was mea-
sured in the EBV-negative Burkitt lymphoma cell line BJAB
(34). Ten micrograms of reporter CAT construct, either
EABSCAT [BMRF1 promoter -333 to +1 (35)] or Z3CAT
(34), was transfected with various amounts of activator
equalized to 3.6 ,ug with pHD1013. Conversion to acetylated
chloramphenicol was quantitated by scintillation counting.
Transfections were repeated at least three times. Activator
constructs were also transfected into the EBV-positive cell
line Raji and assayed for induction of the endogenous viral
BMRF1 transcript (36). The abundance ofthe transcripts was
measured by densitometry.
RESULTS
CKI Phosphorylates ZEBRA in Vitro. E. coli protein prep-
arations containing TrpE-ZEBRA fusion protein or purified
ZEBRA expressed as a nonfusion protein were incubated
with purified CKII and [y32P]ATP. The phosphorylation
products were analyzed by SDS/PAGE followed by autora-
diography (24). Fig. 1C shows that both TrpE-ZEBRA and
purified ZEBRA proteins were phosphorylated, as well as
casein, which served as a positive control. In addition, the
28-kDa subunit of CKII was autophosphorylated in all
reactions. TrpE protein was not phosphorylated by CKII.
Radiolabeled phosphate was not incorporated into ZEBRA
protein when [y32P]ATP was added without CKII (Fig. 2A,
lane 1).
Mapping the Residues ofZEBRA Phosphorylated by CKII in
Vitro. A panel ofZEBRA deletion mutants expressed as TrpE
fusion proteins in E. coli were assayed for the ability to serve
as substrates for CKII phosphorylation (17). The mutant
proteins Z(141-245), Z(1-110 + 160-245), and Z(1-198) were
all phosphorylated (data not shown). This analysis localized
the region recognized by CKII to amino acids 160-198. There
are three serines in this region: S167, S173, and S186 (Fig.
1B). However, S186 is in the center ofthe basic DNA binding
domain and is not associated with the previously described
CKII consensus sequences (22).
The principal target for CKII phosphorylation was deter-
mined by examining ZEBRA proteins mutated at S167 and
S173. The serines at positions 167 and 173 were changed to
alanines singly (ZEBRA S167A, ZEBRA S173A) and to-
gether (ZEBRA S167A/S173A) (Fig. 2). Fig. 2A shows that
full-length ZEBRA and the ZEBRA S167A mutant were
strongly phosphorylated, whereas ZEBRA S173A and the
double mutant were weakly labeled. Therefore, the primary
site of ZEBRA phosphorylated by CKII is S173. The low
level ofphosphorylation ofZEBRA S173A suggests that S167
may be a secondary target for CKII.
CKH Phosphorylation of ZEBRA in Vitro Is Inhibited by
Mutation of the Basic Domain but Not by Mutation of the
Dimerization Domain. S173 is located immediately upstream
of the basic and homodimerization domains required for
DNA binding. To determine whether CKII phosphorylation
was dependent on structures in either of these two domains,
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FIG. 2. CKII phosphorylation of
wild-type and mutant ZEBRA proteins.
(A) Extracts of E. coli normalized for
TrpE fusion protein content by SDS/
PAGE and Coomassie blue staining (data
not shown) were assayed for phosphory-
lation by CKII. Phosphorylated ZEBRA
proteins are indicated with arrows at 70
kDa in lanes 3-7 and at 65 kDa in lane 8.
No specifically phosphorylated species
were detected in the absence of CKII
(lane 1) or in the absence of ZEBRA
sequences (lane 2). (B) Wild-type and mu-
tant ZEBRA proteins were translated and
radiolabeled in vitro in a wheat germ ex-
tract (WGE); the products are -36 kDa
(lanes 2-6) or -31 kDa (lane 7); an aliquot
was crosslinked with glutaraldehyde
(lanes 8-14). Crosslinked products are
indicated by an arrow.
additional ZEBRA mutants were tested in CKII assays.
There was marked reduction in phosphorylation ofa ZEBRA
mutant in which two basic residues have been changed to
acidic ones (M187-189; Fig. 2A, lane 7). A ZEBRA mutant
lacking the dimerization domain [Z(1-198)] was strongly
phosphorylated (Fig. 2A, lane 8). Cross-linking of in vitro
translated proteins indicated that all the ZEBRA mutants
dimerized in solution except Z(1-198) (Fig. 2B). Thus, se-
quences in the basic domain but not in the dimerization region
are required for CKII phosphorylation.
CKU Phosphorylation Inhibits Specific DNA Binding by
ZEBRA. Purified ZEBRA protein or E. coli extract contain-
ing TrpE-ZEBRA fusion protein were preincubated with
CKII and ATP before binding to a 32P-labeled oligonucleotide
containing aZRE and analyzed by EMSA. Equivalent results
were obtained with both expressed forms ofZEBRA (Fig. 3).
Untreated ZEBRA bound an oligonucleotide containing an
AP-1 site as did ZEBRA preincubated with CKII or ATP
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FIG. 3. CKII-mediated phosphorylation inhibits DNA binding by
ZEBRA. Purified ZEBRA protein (A) and TrpE-ZEBRA fusion
protein extract (B) were tested for their ability to bind a radiolabeled
oligonucleotide containing an AP-1 heptamer sequence by EMSA.
ZEBRA proteins were untreated (lane 1), incubated with ATP alone
(lane 2), CKII alone (lane 3), or ATP and CKII (lane 4). Treatment
of CKII phosphorylated proteins with PP2A is shown in lane 5.
alone (Fig. 3, lanes 1-3). However, binding to the AP-1
oligonucleotide was almost completely inhibited when the
ZEBRA proteins were preincubated with both ATP and CKII
(lanes 4). Similar results were obtained with an oligonucle-
otide containing a ZIIIB site (data not shown).
The inhibition of ZEBRA's ability to bind DNA after CKII
phosphorylation was reversible. Both preparations ofZEBRA
that had been phosphorylated by CKII were treated with PP2A
and then analyzed for DNA binding activity (37). PP2A
treatment partially restored DNA binding activity (lanes 5).
ZEBRA Mutation S173A Markedly Reduces DNA Binding
Affinity in Vitro. E. coli extracts containing equal amounts of
wild-type or serine point-mutant TrpE-ZEBRA fusion pro-
teins were tested for DNA binding activity. In Fig. 4, two
oligonucleotides were used as probes in EMSAs: ZIIIB,
which contains a ZRE heptamer present in the viral ZEBRA
promoter; double, which consists of two ZREs (ZIIIA and
ZIIIB) oriented as they appear in the same promoter (4).
Wild-type ZEBRA formed a single shifted band with the
ZIIIB probe and two shifted bands with double (lanes 2 and
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FIG. 4. DNA binding activity of mutant ZEBRA proteins. Bind-
ing of the ZIIIB and double oligonucleotides was examined by
EMSA. Binding activity ofeach mutant was expressed as percentage
of labeled oligonucleotide bound relative to wild type.
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9), presumably representing single and double occupancy of
the oligonucleotide by ZEBRA dimers. Binding by ZEBRA
S167A was reduced to 70% of wild-type activity (lanes 3 and
10). Mutants S173A and S167A/S173A were markedly re-
duced in their capacity to bind both probes, to -10% of
wild-type levels (lanes 4, 5, 11, and 12). Only trace binding
activity was measured with the mutants, which alter the basic
domain (M187-189) or delete the dimerization domain [Z(1-
198)]. The five ZEBRA mutants showed the same relative
reduced affinity for all ZREs tested (data not shown).
Serine Point Mutants of ZEBRA Have Reduced Transacti-
vation Activity in Vivo. The effect of S173 and S167 mutations
on the capacity of ZEBRA to activate transcription in vivo
was tested in two assays. In the first assay, wild-type or
mutant ZEBRA expression constructs were examined for
their ability to activate a cotransfected reporter plasmid in
EBV-negative human B cells (BJAB). The reporter contained
the promoter of a ZEBRA-responsive early lytic cycle gene,
BMRF1, linked to CAT (35). In the second assay, we studied
the ability of wild-type and mutant ZEBRA proteins to
activate transcription of the BMRF1 gene from the latent
EBV genome in Raji cells.
Using reporter gene assays, mutant S167A was -33% as
active as wild-type ZEBRA, whereas S173A was -11% as
active as wild type (averages of data from Fig. SA; data not
shown). Increasing the amount of activator plasmid in the
cotransfection assay compensated for the mutant pheno-
types. Mutants S167A and S173A were, respectively, 22%
and 4% as active as wild type in stimulating transcription of
BMRF1 from the latent genome in Raji cells (Fig. SB). In both
assays the double-mutant S167A/S173A, although severely
impaired relative to wild type, was more active than the single
S173A mutant. All three mutants and wild-type ZEBRA
partitioned to the nucleus to the same extent (data not
shown).
DISCUSSION
Phosphorylation ofZEBRA by CKII. This work reports the
functional consequence of posttranslational modification of
ZEBRA. We define several requirements for phosphoryla-
tion of ZEBRA by CKII and show that phosphorylation of
ZEBRA in vitro inhibits DNA binding. ZEBRA contains two
potential CKII acceptor sites at S167 and S173. Although
these sites are similar, SLEE and SELE, only the latter was
strongly phosphorylated in vitro. The preference for S173
may result from features surrounding the acceptor site; S173
has acidic residues both N-terminal and C-terminal of the
serine and is proximal to the a-helix secondary structure in
the basic domain. Sequences within the basic domain of
ZEBRA are important for CKII phosphorylation since mu-
tating residues 187-189, located 15-17 amino acids down-
stream of the acceptor site, abrogated phosphorylation in
vitro. CKII-mediated phosphorylation of ZEBRA does not
require dimer formation.
These studies do not address the phosphorylation state of
ZEBRA in vivo; however, since CKII is a ubiquitous protein
kinase, it is likely that ZEBRA serves as a substrate for CKII
in vivo. Furthermore, other cellular kinases may react with
ZEBRA in vivo (38). What are the possible functions of a
ZEBRA protein that does not bind DNA as a result of CKII
phosphorylation? Mutant forms of ZEBRA that do not bind
DNA in vitro have been found to activate transcription ofthe
BZLF1 promoter (E. K. Flemington and S. H. Speck, per-
sonal communication; J.L.K., N.T., and G.M., unpublished
data); therefore, in vivo phosphorylated ZEBRA that does
not bind DNA might continue to stimulate its own transcrip-
tion. The ZEBRA protein has a long half-life in vivo (39). The
half-life of the protein might be altered by phosphorylation.
Furthermore, a modified form ofZEBRA that does not bind
DNA may be recruited into a late gene transcription complex,
perhaps by association with late viral proteins (40).
Role of S173 and S167 in DNA Binding and Transcriptional
Activation. Our studies provide the observation that S173 of
ZEBRA, the principal target for CKII phosphorylation, is an
intrinsic component of ZEBRA's DNA binding domain.
Mutation of S173 to alanine resulted in a 90% diminution in
DNA binding activity relative to wild type. Thus, a serine
hydroxyl moiety at position 173 may be necessary to estab-
lish a conformation ofZEBRA permissive for DNA binding.
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Phosphorylation of S173 may disrupt DNA binding and,
therefore, transactivation by shifting ZEBRA into a confor-
mation that restricts DNA binding. ZEBRA differs from
Oct-1 and SRF, whose DNA binding activities are also
regulated by CKII phosphorylation (41, 42). Serine-to-
alanine substitutions in the phosphorylation sites ofOct-1 and
SRF do not impair their capacity to bind DNA.
The decreased ability ofZEBRA mutant S173A to activate
transcription of an EBV early gene in vivo correlated with its
impaired capacity to bind DNA. ZEBRA S167A was also
affected in its capacity to bind DNA and activate transcrip-
tion although to a lesser extent than ZEBRA S173A. Com-
pared to mutant S173A, the double-mutant S167A/S173A
was more active in vivo, even though it was as deficient as
S173A in DNA binding. These results suggest that mutations
of S167 and S173 may affect some property of ZEBRA other
than DNA binding. One explanation for these observations is
that ZEBRA may contact other proteins in order to activate
transcription and disrupt latency. Modification of either S167
or S173 may alter the three-dimensional structure of the
ZEBRA protein in a region that contacts the ancillary factor.
Alternatively, mutation or phosphorylation of S167 or S173
may influence the stability and half-life of the ZEBRA
protein.
Analogy Between ZEBRA and CeUlular Immediate Early
Genes. Stimulation of quiescent cells, in the absence of de
novo protein synthesis, is accompanied by transcription of
cellular early response or immediate early genes. Among
these genes are nuclear proteins, such as c-Myc, c-Fos, and
c-Jun, which are believed to play a role in regulating subse-
quent events in the cell cycle (18). ZEBRA has several
features in common with the cellular immediate early genes.
Its transcription is activated by external stimuli in the ab-
sence of protein synthesis (43, 44) and may be regulated by
SRF, a DNA binding protein that modulates c-Fos transcrip-
tion (45). Also, the DNA binding specificity of ZEBRA
overlaps that of c-Fos/c-Jun (4, 15-17).
Our study demonstrates that ZEBRA, like cellular imme-
diate early genes, has functional CKII phosphorylation sites
N-terminal to its DNA binding domain. Moreover, CKII
phosphorylation ofZEBRA inhibits DNA binding. The gen-
eral structure N-terminal kinase site/DNA binding domain
(kbZIP) appears to be a conserved motifby which the activity
of a DNA binding protein can be modulated by kinases and
phosphatases in response to mitogenic and other external
stimuli. The biologic role of ZEBRA as an immediate early
gene in the EBV lytic life cycle may be analogous to imme-
diate early genes that initiate the cell cycle. The virus may
respond to external stimuli and changes in patterns of cell
growth via changes in the phosphorylation state of ZEBRA.
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